BDVC yields 57.14% · ABBV yields 3.12%● Live data
📍 BDVC pulled ahead of the other in Year 1
Combined, BDVC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BDVC + ABBV for your $10,000?
Franklin BSP Lending Corporation is a business development company specializing in investing in middle market companies, leverage buyouts, acquisitions, recapitalizations, growth opportunities, venture debt, CLO equity, delayed draw term loans, rescue financing, distressed or turnaround situations, and bridge loans and financing. It invests in the debt and equity of private held companies. It typically prefers to invest in unitranche, senior secured debt, senior unsecured debt, second lien secured debt, equity co-investments, subordinated secured debt, subordinated unsecured debt, mezzanine debt, convertible debt, convertible preferred equity, preferred equity, common equity, warrants. It seeks to invest in business services, energy, general industrial, government, healthcare, software, specialty finance; restaurants, TMT, food and beverage, and consumer products. It prefers to take majority stakes in investments. It invests throughout the United States and Canada. It invests between $1 million and $25 million in established companies with revenues between $5 million and $1000 million and stable operating cash flows. Within middle market loans, the investment size across the BSP private debt platform typically ranges from $25 million to over $250 million in companies with EBITDA between $10 million and $100 million. It seeks to have Board representation or Board Observation rights in its portfolio companies.
Full BDVC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.